FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 361:1301-1303 September 24, 2009 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Löwenberg, B. Related Article by Fernandez, H. F. PubMed Citation

Acute myeloid leukemia (AML) is a heterogeneous hematologic cancer whose wide range of outcomes probably reflects the accumulation of various acquired mutations that block the differentiation of blood-cell progenitors or confer a proliferative advantage to the malignant clone. Current therapies can cure approximately 40% of young patients, but outcomes are much worse in patients over the age of 60 years, who constitute the majority of cases of AML.

An older age, a poor performance status, a high white-cell count, previous exposure to genotoxic agents, or the diagnosis of a myelodysplastic syndrome preceding the diagnosis of AML all negatively influence the . . . [Full Text of this Article]

Source Information

From the Department of Clinical Hematology and Immunology, Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris (AP-HP), Université Paris 7, Paris (H.D.); and the Department of Hematology, Hôpital Avicenne, AP-HP, Université Paris 13, Bobigny (C.G.) — both in France.

This article has been cited by other articles:

• (2009). Daunorubicin for Older Adults with Acute Myeloid Leukemia. JWatch Oncology and Hematology 2009: 2-2 [Full Text]